广泛期小细胞肺癌二线化疗后应用安罗替尼的疗效及安全性观察

摘要/Abstract

摘要： 目的本研究致力于评价盐酸安罗替尼胶囊针对接受了常规二级化疗但仍未获得有效控制的广泛期小细胞肺癌（SCLC）的治疗,研究该药物在常规二级化疗但仍未获得有效控制的广泛期SCLC中的有效性和安全性。方法选取2018年5月—2018年10月福建省立医院肿瘤内科收治的广泛期SCLC二线化疗后进展或不良反应不能耐受的病例13例,PS 0~2分,予以标准剂量安罗替尼治疗,若患者出现安罗替尼不可耐受不良反应可予以安罗替尼减量,观察分析安罗替尼对二线治疗后的广泛期SCLC疗效及安全性。主要观察指标为无疾病进展时间（PFS）和总生存期（OS）。次要观察指标为神经元特异性烯醇化酶（NSE）水平及安罗替尼的安全性。从而为安罗替尼的应用提供相应的临床依据。结果经过2~6个周期的治疗,发现安罗替尼的mPFS为5.2个月（95% CI 5.0~5.4）;mOS为 7.0个月。安罗替尼的NSE有所降低。虽然总体不良反应比例达到75%,其中3/4级不良反应的比例仅有5%。结论安罗替尼是一种治疗SCLC的药物,它能够控制疾病的发展,并且有一定的疗效;使用安罗替尼进行SCLC的三线治疗能够显著改善患者的PFS和OS,并且具有较强的安全性和耐受性。

关键词: 小细胞肺癌, 安罗替尼, 疾病进展时间, 疗效, 不良反应

Abstract: Objective This study aims to evaluate the efficacy and safety of anlotinib hydrochloride capsules in broad-stage small cell lung cancer(SCLC) patients that have received conventional secondary chemotherapy but still received no effective control, to study the efficacy and safety of this drug in broad-stage SCLC with conventional secondary chemotherapy but still no effective control. The primary outcome measures were time to no disease progression (PFS) and overall survival (OS). Methods A total of 13 extensive stage SCLC patients were selected who were reated at Fujian provincial hospital medical oncology from May 2018 to October 2018. Among these patients,progression or advers reactions after chemotherapy happened, with PS 0-2 points. the standard dose anlotinib treatment were given to them,and if patients suffered from intolerance advers reactions ,the dose of anlotinib can be reduced.The observation and analysis of anlotinib for second-line treatment of extensive SCLC were done for evaluation of drug efficacy and safety. The primary study endpoints were PFS and OS, and the secondary study endpoints were NSE level and safety of anlotinib,so as to provide the corresponding clinical basis for the promotion and application of anlotinib. Results After two to six cycles of treatment, we found that the mPFS of anlotinib was 5.2 months (95%CI 5.0~5.4); mOS 7.0 months. NSE decreased with anlotinib. Although the overall proportion of side effects reached 75%, only the proportion of grade 3/4 side effects was 5%. Conclusion Anlotinib is a treatment for SCLC that controls the development of the disease and has some efficacy; Third-line treatment of SCLC with anlotinib can significantly improve PFS and OS and has strong safety and good tolerability.

Key words: small-cell lung cancer, anlotinib, time for disease progress, effectiveness, adverse reaction

中图分类号:

R734.2

郑建萍, 崔同建. 广泛期小细胞肺癌二线化疗后应用安罗替尼的疗效及安全性观察[J]. 中华养生保健, 2024, 42(10): 163-166.

ZHENG Jian-ping, CUI Tong-jian. The Efficacy and Safety of Anlotinib Following Second-Line Chemotherapy for Extensive Stage Small-Cell Lung Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(10): 163-166.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et a1. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians,2018,68:394-424.
[2] HOWLADER N, NOONE AM, KRAPCHO M, et a1. SEER Cancer Statistics Review, 1975-2010[EB/OL].(2013-12)[2024-03].https://seer.cancer.gov/archive/csr/1975_2010/.
[3] RUDIN C M, ISMAILA N, HANN C L, et a1. Treatment of small-cell lung cancer:American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline[J]. J Clin Oncol,2015,33(34):4106-4111.
[4] FRÜH M, DE RUYSSCHER D, POPAT S, et a1. Small-cell lung cancer (SCLC):ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2013,24(suppl 6):99-105.
[5] ÁNGEL ARTAL CORTÉS, GóMEZ M D, POUS A F, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer[J]. Clin Transl Oncol,2010,12(1):27-31.
[6] GEORGE J, LIM J S, JANG S J, et a1. Comprehensive genomic profiles of small cell lung cancer[J]. Nature,2015,524(7563):47-53.
[7] STAHEL R A, GINSBERG R, HAVEMANN K.Staging and prognostic factors in small cell lung cancer: a consensus report[J]. Lung Cancer, 1989, 5(89):119-126.
[8] SCHNEIDER B J, SAXENA A, DOWNEY R J.Surgery for early-stage small cell lung cancer[J]. J Natl Compr Canc Netw,20ll,9(10):1132-1139.
[9] TAKAHASHI T, YAMANAKA T, SETO T, et al.Prophylactic cranial irradiation versus observation in patients with extensivedisease small-cell lung cancer:A multicentre,randomised,open-label phase 3 trial[J]. Lancet Oncol,2017,18(5):663-671.
[10] RECK M, BONDARENKO I, LUFI A, et a1. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease small cell lung cancer:results from a randomized,double-blind,multicenter phase 2 trial[J]. Ann Oncol,2013,24(11):75-83.
[11] FONTANINI G, FAVIANA P, LUCCHI M, et a1. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavorable prognosis in operated small cell lung carcinoma[J]. Br J Cancer,2002,86(4):558-563.
[12] LI Q, WU T, JING L, et a1. Angiogenesis inhibitors for the treatment of small cell lung cancer (SCLC):a meta-analysis of 7 randomized controlled trials[J]. Medicine,2017,96(13):e6412.
[13] TISEO M, BONI L, AMBROSIO F, et a1. Italian,multicenter,phase Ⅲ, randomized study of cisplatin plus etoposide with or without bevacizumabas first-line treatment inextensive-disease small-cell lung cancer:the GOIRC-AIFA FARM6PMFJM trial[J]. J Clin Oncol,2017,35(12):1281-1287.
[14] READY N E, PANG H H, GU L, et a1. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized,double-blind,placebo-controlled phase Ⅱ study-CALGB 30504(alliance)[J]. J Clin Oncol,2015,33(15):1660-1665.
[15] CHENG Y, WANG Q M, LI K, et a1. Anlotinib as third-line or further-line treatment in relapsed SCLC:a multicentre,randomized,double-blind phase 2 trial[J]. Br J Cancer,2021,125:366-371.